Nebivolol Glenmark Pharmaceuticals Europe (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Glenmark Pharmaceuticals Europe, is a selective β1‑adrenergic antagonist presented as an oral tablet for systemic use. It is indicated for the management of hypertension, helping to reduce elevated blood pressure in adult patients by decreasing heart rate and peripheral vascular resistance.

GNH USA supplies Nebivolol Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets through validated supply chains and regulatory compliance.

Nebivolol is a selective β1‑blocker used in the management of high blood pressure conditions.

- Essential hypertension: Lowers systolic and diastolic blood pressure, improving overall cardiovascular risk. - Isolated systolic hypertension: Reduces elevated systolic pressure while maintaining cardiac output. - Diastolic hypertension: Decreases diastolic pressure, aiding in blood pressure control.

Nebivolol may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Headache: mild to moderate discomfort. - Dizziness: often related to blood pressure lowering. - Fatigue: feeling of reduced energy. - Bradycardia: slower than normal heart rate. - Nausea: mild gastrointestinal upset. - Nasal congestion: mild upper‑respiratory irritation.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction. - Bronchospasm: difficulty breathing, especially in asthmatic patients. - Allergic reaction: rash, itching, or swelling. - Liver enzyme elevation: abnormal hepatic function tests. - Heart failure exacerbation: worsening of existing cardiac insufficiency.

Before initiating Nebivolol therapy, consider the following safety measures.

- Monitor heart rate: ensure baseline and periodic checks to avoid excessive bradycardia. - Assess respiratory status: use caution in patients with asthma or chronic obstructive pulmonary disease. - Evaluate hepatic function: dose adjustment may be needed in liver impairment. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Pregnancy and lactation: consult a healthcare professional before use. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol can interact with several medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Combined use with other beta‑blockers: risk of excessive heart rate reduction. - Co‑administration with calcium‑channel blockers verapamil or diltiazem: may cause profound bradycardia or AV block. - Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides, loop diuretics): may enhance antihypertensive effect, requiring blood pressure monitoring. - ACE inhibitors or ARBs: additive blood pressure lowering, watch for hypotension. - NSAIDs: may attenuate antihypertensive response, monitor blood pressure regularly.